FIELD: medicine, pharmaceutics.
SUBSTANCE: there are described injectable pharmaceutical depot formulations containing a free base of ziprasidone or its pharmaceutically acceptable salt, pharmaceutically acceptable carrier, and preferentially at least two surface stabilisers. Said compound of ziprasidone is presented in the form of nanoparticles of mean particle size less than approximately 2000 nm.
EFFECT: invention provides maintained effective mean particle size of the compound of ziprasidone, and sterilisation and storage stability of the formulation.
22 cl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
TREATING AND PREVENTING HIV INFECTION | 2010 |
|
RU2569058C2 |
ARIPIPRAZOLE PRODRUG COMPOSITIONS | 2015 |
|
RU2817019C2 |
DEPO-PREPARATIONS OF ACTIVE ARYLHETEROCYCLIC SUBSTANCES IN SLURRY FORM | 2003 |
|
RU2292207C2 |
ARIPIPRAZOLE PRODRUG COMPOSITIONS | 2015 |
|
RU2705376C2 |
PHARMACEUTICAL COMPOSITION, METHODS FOR ITS PREPARING, STABLE WATER-INSOLUBLE COMPLEXES, METHOD FOR CONVERSION OF THERAPEUTICALLY ACTIVE COMPOUND AND THERAPEUTICALLY ACTIVE COMPOUND | 1999 |
|
RU2240827C2 |
CRYSTALLINE FORM OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | 2008 |
|
RU2498979C2 |
DRUG DELIVERY COMPOSITION | 2010 |
|
RU2589823C2 |
NOVEL DEPOT-PREPARATIONS FOR INJECTION | 2003 |
|
RU2310450C2 |
STABLE COMPOSITIONS OF NANOPARTICLES | 2006 |
|
RU2409352C2 |
COMPOSITIONS AND METHODS OF ACTIVE PHARMACEUTICAL INGREDIENT STABILISATION | 2005 |
|
RU2391115C2 |
Authors
Dates
2010-12-27—Published
2006-04-10—Filed